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Abstract
Background: Time to clinical stability is a well-defined early clinical outcome in hospitalized
patients with community-acquired pneumonia, but it has not been evaluated in patients with
ventilator-associated pneumonia (VAP). The objective of this study was to compare time to clinical
stability in patients with MRSA VAP treated with linezolid versus vancomycin.
Methods: This was a secondary analysis of the IMPACT-HAP study database. VAP was defined
according to CDC criteria. MRSA VAP was considered when MRSA was isolated from a tracheal
aspirate or bronchoalveolar lavage. A patient was considered to reach clinical stability the day
that the following four criteria were met: 1) Afebrile for 24 hours, 2) Decrease in WBC >10% or
WBC within normal range, 3) Improving of PaO2/FiO2 ratio of >20%, or PaO2/FiO2 ratio >250,
or extubation, or FiO2 ≤ 30% if extubated, and 4) Systolic blood pressure >90 mmHg. Time to
clinical stability for linezolid and vancomycin were compared using the Chi-Squared and Student’s
t-tests.
Results: A total of 89 patients treated with linezolid and 75 patients treated with vancomycin
met study criteria. From the population of linezolid treated patients, 79% reached clinical stability,
compared to 75% of the population of vancomycin treated patients (P=0.463). Median time to
clinical stability was 6 days (IQR 8) for patients treated with linezolid, versus 7 days (IQR 12) for
patients treated with vancomycin (P=0.490).
Conclusions: This study failed to demonstrate a statistically significant difference in time to clini-
cal stability in patients with MRSA VAP treated with linezolid or vancomycin. The number of days
for patients to reach clinical stability can be used as an early clinical outcome in patients with VAP.
DOI: 10.18297/jri/vol1/iss1/4
Received Date: October 17, 2016
Accepted Date: November 22, 2016
Website: https://www.louisville.edu/jri
Affiliations:
University of Louisville Division of Infectious Dis-
eases, Louisville: (PP, TLW, JAR)
Division of Infectious Diseases, Henry Ford Hos-
pital, Detroit: (MJZ)
Division of Pulmonary and Critical Care
Medicine, University of Miami/Jackson Memorial
Hospital, Miami: (DHK)
Summa Health System, Akron: (TMF)
Michigan State University, East Lansing: (GES)
Specialty Care Medicines Development Group,
Pfizer, Inc, Collegeville: (KDF)
1 Background
It has been recently reported that in the US, pneumonia along
with surgical site infections are the leading causes of healthcare-
associated infections and almost 40% of the pneumonia events
are related to the use of mechanical ventilation.1
Clinical trials are necessary to evaluate new treatment options
for hospital-acquired pneumonia (HAP) including ventilator-
associated pneumonia (VAP). Controversy still exists regarding
the optimal end-point for these patients.2 All-cause mortality
and to a lesser degree attributable mortality have been the "gold
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standard" clinical outcomes utilized in HAP studies based on the
available evidence.3 Time to event outcomes such as duration of
ICU, hospital length of stay and mechanical ventilation have been
much less analyzed.2
Over the recent years the FDA has updated the recommendations
for the industry regarding clinical trials and early evaluations
of study endpoints have been suggested for community-acquired
pneumonia (CAP) as well as other infections.4–6 However, FDA
recommendations for HAP antibiotics trials still proposed primary
efficacy endpoints mortality and survival to be evaluated between
day 14 and 28 proposing other secondary endpoints such as clin-
ical resolution at 7-14 days after completion of treatment, length
of stay in the hospital, and days on mechanical ventilation.7 Opti-
mal antibiotic therapy will decrease the bacterial load in the lung,
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which in turn could reflect in an early improvement of signs and
symptoms. The late evaluation of outcomes may not be able to
detect differences between antibiotics and time to clinical stabil-
ity over the first week of the infection could be the endpoint that
more closely relates to this activity.
Time to clinical stability is a well-defined early clinical outcome in
hospitalized patients with CAP and a well-defined early efficacy
endpoint to be used in clinical trials for CAP.4 Several guidelines
for the management of patients with CAP have established cri-
teria to define when a patient reaches clinical stability.8,9 White
blood cell count (WBC), temperature, and respiratory symptoms
are within the criteria commonly used.
On the contrary, fewer studies have been published evaluating pa-
tients with VAP and these studies all utilized absolute resolution
of the criteria used to define clinical stability.10–14 Clinical resolu-
tion has been described to be between 3 and 10 days depending
on the cohort of patients being evaluated. Patients with VAP due
to MRSA have a longer time to resolution when compared with
patients with VAP due to MSSA or H influenza.14 The presence of
ARDS (Acute respiratory distress syndrome) also delays clinical
resolution.13
In the field of clinical research on CAP, time to clinical stability
has been used as a clinical outcome to compare effectiveness of
initial intravenous antibiotics.15 During the initial 7 days of an-
timicrobial therapy, a number of patients will reach clinical sta-
bility. It can be hypothesized that those antibiotics with better
activity against the etiologic organism may produce an early time
to clinical stability and therefore increase the number of patients
reaching clinical stability by day 7. None of the published data
on VAP has evaluated the impact of antibiotic treatment in time
to clinical stability.
The primary objective of this study was to compare time to clinical
stability in patients with MRSA VAP treated with linezolid versus
vancomycin. Secondary objectives were: 1) to compare the num-
ber of patients reaching time to clinical stability, 2) to compare




This was a secondary analysis of The Improving Medicine through
Pathway Assessment of Critical Therapy in Hospital-Acquired
Pneumonia (IMPACT-HAP), a multicenter, retrospective, observa-
tional study of intensive care unit (ICU) patients with VAP due
to MRSA treated with linezolid or vancomycin. Patients were
enrolled from 5 sites in the United States: the University of
Louisville Medical Center (Louisville, KY); the Henry Ford Health
System (Detroit, MI); the University of Miami/Jackson Memorial
Hospital (Miami, FL); the Summa Health System (Akron, OH);
and Michigan State University (East Lansing, MI). Data were
collected from November 2008 through October 2012. Patient
data were collected on a case report form, entered into a web-
based database, and transferred electronically to the University of
Louisville Clinical and Translational Research Support Center for
data validation and quality. The study was approved by the insti-
tutional review board at each participating institution (University
of Louisville Human Subjects Protection Program Office; Summa
Health System Institutional Review Board; Michigan State Uni-
versity Human Research Protection Program; Henry Ford Health
System Institutional Review Board; University of Miami Human
Subjects Research Office), all of which waived the requirement




• VAP was defined according to the Centers for Disease Con-
trol and Prevention National Healthcare Safety Network
surveillance definitions.16 VAP was considered to be due
to MRSA when MRSA was isolated from tracheal aspirates,
bronchoalveolar lavage (BAL) obtained by bronchoscopy, or
blinded BAL. Patients must have received more than 48
hours of either vancomycin or linezolid. Vancomycin was
dosed based on blood levels according to standard of care.
2.2.2 Exclusion Criteria
• Data used to define clinical stability criteria missing for more
than 2 consecutive days
• Comfort care or a do not resuscitate order
• Clinical failure during the initial 48 hours of antibiotic ther-
apy
• In clinical practice, ICU physicians change antibiotics due
to their own preferences without the evidence of patients’
clinical deterioration. Patients were also excluded if there
was a switch from vancomycin to linezolid or vice versa after
48 hours in a patient without evidence of clinical failure.
2.2.3 Study Groups
Patients were included in the linezolid group if they received line-
zolid within 48 hours of diagnosis and received at least 5 con-
secutive days of linezolid therapy. Patients were included in the
vancomycin group if they received vancomycin within 48 hours of
diagnosis and received at least 5 consecutive days of vancomycin
therapy.
2.2.4 Clinical Stability Criteria
The following four criteria were used to evaluate clinical stability:
1. Afebrile for 24 hours
2. Decrease in WBC >10% (or WBC within normal range)
3. Improving of PaO2/FiO2 ratio of >20% (or PaO2/FiO2 ratio
>250), or extubation, or FiO2 ≤ 30% if extubated
4. Systolic blood pressure >90 mmHg.
Variables were collected daily from day 0 (day of diagnosis of
VAP) to day 14 if available. If a value was missing on one day,
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Age, Median (IQR) 60 (20) 55 (27.5) 0.205
Male Sex, n (%) 54 (61) 42 (56) 0.633
Body Mass Index, Median (IQR) 28.9 (12) 27.5 (10.1) 0.1
Nursing Home Residence, n (%) 6 (7) 4 (5) 0.756
Comorbidities
Bronchiectasis, n (%) 7 (8) 1 (1) 0.072
Cardiac Disease, n (%) 28 (31) 24 (32) >0.999
Diabetes, n (%) 26 (29) 13 (17) 0.097
Renal Disease, n (%) 7 (8) 6 (8) >0.999
Respiratory Disease, n (%) 24 (27) 15 (20) 0.359
Active Cancer, n (%) 8 (9) 5 (7) 0.773
COPD, n (%) 15 (17) 6 (8) 0.515
End-Stage Liver Disease, n (%) 7 (8) 1 (1) 0.072
Steroids, n (%) 4 (4) 6 (8) 0.515
Vascular Disease, n (%) 19 (21) 22 (29) 0.279
Risk Factors for MDROs, n (%)
Home Infusion Therapy, n (%) 2 (2) 0 (0) 0.501
Hospitalization for ≥2 days in prior 90 days, n (%) 19 (21) 16 (21) >0.999
Home Wound Care, n (%) 5 (6) 3 (4) 0.728
Hospitalized for ≥5 days before start of HAP therapy, n (%) 65 (73) 43 (57) 0.047
Prior colonization with an MDRO, n (%) 32 (36) 30 (40) 0.63
Any risk Factors for MDROs, n (%) 76 (85) 62 (83) 0.672
Severity of Disease
APACHE II Score, Median (IQR) 21 (10) 19 (9) 0.014
CPIS on Day 0, Median (IQR) 7 (3) 6 (2) 0.041
CPIS on Day 3, Median (IQR) 7 (3) 7 (3) 0.065
Severe Sepsis, n (%) 69 (78) 48 (64) 0.06
Multilobar Infiltrates, n (%) 37 (42) 24 (32) 0.257
Empiric Therapy based on Guidelines
Appropriate Empiric Therapy, n (%) 88 (99) 73 (97) 0.593
APACHE: Acute Physiology and Chronic Health Evaluation; COPD: Chronic Obstructive Pulmonary Disease;
CPIS: Clinical Pulmonary Infection Score; ESLD: End-Stage Liver Disease; ESRD: End-Stage Renal Disease;
MDRO: multidrug-resistant organism
the last observation was carried forward. If a second value was
missing, the next observation was carried backward. Values that
have been carried forward or backwards were not considered to
meet clinical stability unless they were within normal ranges.
A patient was considered to have reached clinical stability on the
day that all four criteria for clinical stability were met. Patients
who died during the first 2 weeks after the diagnosis of VAP were
classified as not reaching clinical stability and assigned the worse
outcome (day 14).
2.2.5 Outcome variables
1. Primary Outcome: Time to clinical stability
2. Secondary Outcomes:
(a) Population of patients reaching time to clinical stability
The number of patients who reached clinical stability
between day 1 and 14 after the diagnosis of VAP was
calculated for both study groups.
(b) Mortality
All-cause mortality within 30 days after VAP diagno-
sis was assessed for the linezolid and the vancomycin
groups including those who reached clinical stability.
2.2.6 Confounding variables
At the time of clinical diagnosis of pneumonia (day 0), data on
patients’ demographic and baseline characteristics, severity of ill-
ness including the Acute Physiology and Chronic Health Evalu-
ation (APACHE) II score and the Clinical Pulmonary Infection
Score (CPIS), diagnostic procedures, and treatment were col-
lected. While hospitalized, patients were followed until dis-
charge, death, or 28 days after VAP diagnosis, whichever occurred
first. Vital signs and laboratory values were collected during hos-
pitalization. Identification of MRSA isolates and in vitro suscep-
tibility were performed at each participating center. Vancomycin
serum trough levels were collected throughout the study period.
2.2.7 Statistical Analysis
Categorical variables were expressed as frequencies and percent-
ages and were compared between the two treatment groups us-
ing Chi-square or Fisher’s Exact tests. Continuous variables were
expressed as medians and interquartile ranges or means and stan-
dard deviations and were compared between the two groups us-
ing the Mann-Whitney U-test or Student’s t-test.
2.2.8 Multivariate analysis for time to clinical stability
To compare the adjusted effect of therapy on the time to clinical
stability, Accelerated Failure Time models were used. Since these
models require a pre specified distribution, we evaluated eight
possible models and reported the results of the model with the
lowest Akaike Information Criterion (log normal model). Clini-
cally significant confounding variables, as deemed by the research
team, were selected for adjustment in the multivariable models.
This model was adjusted for the following variables: age, sex,
BMI, risk factors for multidrug resistant organisms, bronchiec-
tasis, COPD, vascular disease, diabetes, multilobar infiltrates on
chest image, severity of disease on day 0 (CPIS, severe sepsis, and
APACHE II score), and appropriate empiric therapy based on na-
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Fig. 1 Adjusted effect of therapy on the time to clinical stability.
Dotted lines show the 95% confidence interval
tional guidelines recommendation. Adjusted survival curves were
created to compare the two groups. R v3.2.2 was used for all
analysis. P-values of ≤0.05 were considered statistically signifi-
cant in all analyses unless otherwise specified.
3 Results
A total of 89 patients treated with linezolid and 75 patients
treated with vancomycin met study criteria and are included in
the analysis. Baseline characteristics of the study population are
shown in Table 1.
3.1 Time to clinical stability
The median time to clinical stability was 6 days (IQR 8) for pa-
tients treated with linezolid, versus 7 days (IQR 12) for patients
treated with vancomycin (P=0.490). The adjusted effect of ther-
apy on time to clinical stability is shown in Fig. 1.
3.2 Proportion of patients who reached clinical stability
From the population of linezolid treated patients, 79% (70 pa-
tients) reached clinical stability within 14 days of VAP diagnosis,
compared to 75% (56 patients) of the population of vancomycin
treated patients (P= 0.463).
3.3 Mortality
All cause-mortality within 30 days for the total study was 18%
(16 patients) for the linezolid group versus 17% (13 patients) for
the vancomycin group (P>0.959). Of the patients who reached
clinical stability, the mortality within 30 days of diagnosis was 6%
(5 patients) for the linezolid group versus 7% (4 patients) for the
vancomycin group (P>0.999).
4 Discussion
This study failed to demonstrate a statistically significant differ-
ence in time to clinical stability in patients with MRSA VAP treated
with linezolid or vancomycin. The median time to clinical stabil-
ity was 6 days (IQR 8) for patients treated with linezolid, versus 7
days (IQR 12) for patients treated with vancomycin (P=0.490).
This time to clinical stability occurred in patients who received
appropriate empiric therapy. A longer time to clinical stability is
expected in the event of inappropriate empiric. If this 1-day dif-
ference in reaching clinical stability happens to be accurate, 2,178
patients will be needed in order to assure enough power to detect
a statistically significant difference.
No prior studies in VAP have defined criteria for clinical stabil-
ity. Considering well-established criteria in the field of CAP, we
selected lack of fever and improvement in WBC as part of the
criteria for clinical stability. Prior studies evaluating the clinical
course of patients with VAP have used PaO2/FiO2 ratio, CPIS, and
microbiology. In these studies, a fix predetermined value was se-
lected to define resolution, such as PaO2/FiO2 ratio ≥ 250, or
negative micro results.10–14 Meeting these criteria practically de-
fines the time when the particular abnormality is back to normal
but fails to define when it is improving. In an attempt to define
improvement, we compared WBC count and oxygenation with
the values of the prior day and define a level of change that will
be considered as improvement.
The number of days to reach clinical stability for both study
groups is within the range reported in the literature for time
to resolution of symptom,10–14 and is close to the already well-
established time to clinical stability of CAP. Early clinical improve-
ment at day 3 to 5 has been used as the primary efficacy end-
point in CAP clinical trials based on recommendations from the
Food and Drug Administration.4 However, primary endpoint for
hospital-acquired and ventilator-associated pneumonia remains
to be evaluated at 14 to 28 days and clinical stability considered
a secondary endpoint.7
Several CAP studies evaluating the safety of switch therapy
showed that reaching clinical stability is associated with resolu-
tion of infection and good clinical outcomes.17,18 However, reach-
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ing clinical stability in VAP is still associated with higher mortality
rates likely due to underlying diseases19,20 Our data emphasizes
the challenge of selecting mortality as an outcome in patients with
VAP, since the mortality at 30 days still occurred in 5-10% of the
patients reaching clinical stability. The number of days for pa-
tients to reach clinical stability could be an early clinical outcome
used when comparing different antibiotics for therapy of VAP.
The primary limitation of this study is that in an attempt to evalu-
ate antibiotic effectiveness against MRSA VAP, patients with clin-
ical failure during the initial 48 hours of diagnosis of VAP were
excluded from study. By excluding this sicker population, the
number of patients reaching clinical stability and the time to clin-
ical stability was likely biased. There are several other limitations
in this study that are due to the retrospective, observational na-
ture of the study. Furthermore, patients included in the database
were randomly selected and did not represent consecutive cases
of hospitalized patients with VAP. Being a secondary analysis with
a small number of patients and no sample size calculation, this
study may have not been powered to detect statistically signifi-
cant differences.
In conclusion, our data suggest that time to clinical stability may
be used as an early clinical outcome in patients with VAP, bet-
ter reflecting antibiotic activity. Late outcomes, such as mortal-
ity, may represent a combination of antibiotic activity as well as
severity of underlying conditions that predispose the patient to
develop VAP.
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